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ABSTRACT 
 
 ARDS is a lung condition characterized by impaired gas exchange with systemic 
release of inflammatory mediators, causing inflammation, hypoxemia and multiple organ 
failure.  Disease susceptibility and progression are poorly understood and there are few 
effective therapeutic options.  Existing biomarkers have limited effectiveness as 
diagnostic and therapeutic targets.  Whole-exome sequencing is an effective tool in 
detection of disease-causing genetic variants in complex genetic conditions such as acute 
respiratory distress syndrome (ARDS).   
To identify disease-causing variants in ARDS patients, whole-exome sequencing 
was performed on 96 patient DNA samples from the National Heart, Lung and Blood 
Institute’s ARDS Network (ARDSnet). By comparing these exome data with 625 
participants of the 1000 Genomes Project, we have tentatively identified a number of 
single nucleotide polymorphisms (SNP) which are potentially associated with ARDS. In 
this study, we validated three SNPs (rs78142040, rs9605146, and rs3848719) in an 
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additional 117 ARDS patients using TaqMan SNP genotyping assays (Life Technologies) 
to substantiate their associations with the susceptibility, severity and outcome of ARDS.   
rs78142040 (C>T) occurs within a histone mark in intron 6 of the Arylsulfatase D 
gene.  rs9605146 (G>A)(also known as rs114989947) causes a coding change (proline to 
leucine) with a deleterious effect in the XK, Kell blood group complex subunit-related 
family, member 3 gene. rs3848719 (G>A) is a synonymous SNP in exon 5 of gene Zinc-
Finger/Leucine-Zipper Co-Transducer NIF1.  rs78142040 and rs9605146 are 
significantly associated with susceptibility to ARDS[minor allele frequency (MAF): 
0.219 versus 0.003 (control), p<2.95×10-7 and 0.386 versus 0.046 (control), p<2.95×10-7; 
respectively]. rs3848719 (MAF 0.394 in cases, 0.287 in controls) is associated with 
APACHE II score when the score quartiles are compared (p=0.032 OR=0.549, 
95%CI=0.313-0.96) and Rs78142040 approaches significant association with APACHE 
II score (p=0.061). rs78142040 is associated with the 60-day mortality in the 213 ARDS 
patient population (p=0.017, OR=2.039, 95%CI=1.130-3.681). The same trends hold by 
stratification of patient population and comorbidity variables. All SNPs are in Hardy-
Weinberg Equilibrium (HWE p>1×10-4) in our cases.  These 3 SNPs have not been 
previously associated with ARDS and represent potential new genetic biomarkers for 
ARDS.  More validations in larger patient populations and further exploration of 
underlying molecular mechanisms are warranted.  
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GLOSSARY 
 
 
Acute respiratory distress syndrome: (ARDS) A severe condition resulting from illness 
or injury and is characterized by inflammation and fluid buildup in the lungs.  Oxygen is 
incapable of crossing from the lungs into the blood.   
Allele: One of a number of alternate nucleotides of a specific locus on a strand of DNA.  
Amino acid: Organic acids that form the building blocks of proteins.  Each of the 20 
amino acids are coded by a 3 nucleotide DNA sequence. 
Deoxyribonucleic Acid (DNA): Nucleic acids that encode genetic instructions of all 
living organisms. 
Eigenvalue (principal component): magnitude of the variation along the eigenvector 
which is identified using principal component analysis.  The product of a non-zero 
eigenvector and a square matrix. 
Eigenvector:  Axis of variation that is identified using principal component analysis. 
Eigenvectors are defined as non-zero vectors associated with matrix equations. 
Exon: DNA sequence that remains in the mature RNA of a gene after introns are 
removed. 
Exome: Genome sequence that is transcribed to the mature RNA, comprised of all of the 
exons. 
Exome-seq: Exome sequencing is a method of DNA sequencing that selectively 
sequences protein coding regions of the genome (exons). 
Genome: The total genetic material of an organism. 
Genome-wide association study: case-control study examining the association of 
common genetic variants with other traits. 
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Genotype: The set of alleles that an organism possesses for a given genetic locus. 
Normally a genotype contains 2 alleles due to the presence of 2 chromosomes.   
Haplotype: A combination of nearby alleles that are inherited together more frequently 
than expected.   
Hardy-Weinberg Equilibrium (HWE): The expected distribution of genotypes giving 
the existing allele counts according to the equation (p+q)2=p2+2pq+q2 , where the alleles 
are p and q. In HWE, allele and genotype frequencies remain consistent across 
generations. 
Intron: DNA sequence in a gene but is not transcribed into the mature RNA. 
Linkage disequilibrium: When alleles for two genetic loci are not distributed randomly 
the loci are in linkage disequilibrium. 
Major allele: For a genomic position the allele that occurs most frequently in a 
population is the major allele. 
Manhattan plot: A plot of the genetic variant location vs. the –log10 (χ2 p-value). It is 
used to visualize associations across the genome in a population. 
Mendelian disease: Diseases that have simple genetic inheritance patterns and are 
caused by a small number of genes.  
Minor allele: For a genomic position an allele that occurs in a population less frequently 
than a different allele at the same position is called a minor allele. 
Next generation sequencing (NGS): Current high throughput genetic sequencing 
technology, which produces the order of nucleotides within a DNA molecule.  
Nonsynonymous mutation: A genetic variant which causes a change in amino acid 
coding. 
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Principal component: See eigenvalue. 
Principal component analysis (PCA): A mathematical method for identifying and 
adjusting for axes of variation within a dataset.  PCA uses an orthogonal transformation 
to convert variables into linearly uncorrelated variables we call eigenvalues. 
Q-Q plot (quantile-quantile plot): Compares the expected and actual values for a 
probability distribution (commonly the χ2, χ2 p-value, or the Hardy-Weinberg p-value). 
Scree plot: A plot of the magnitude of the eigenvalues.  This type of plot is used to 
visualize eigenvalues produced by principal components analysis that may be retained in 
association tests. 
Single nucleotide polymorphism (SNP): Genetic variant that occurs at one nucleotide  
 (base pair).  Different alleles are observed at one position across a population.   
Synonymous mutation: A genetic variant in a protein coding region that causes no 
change in amino acid coding. 
Whole-exome sequencing: (WES) see Exome-Seq 
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CHAPTER 1 
 
INTRODUCTION 
 
 
 
Acute respiratory distress syndrome (ARDS), a severe form of acute lung injury, 
is characterized by the inflammation and fluid build-up of the alveoli in the lungs, which 
reduces the ability of oxygen to cross over into the blood stream1,2. ARDS has an 
extremely high mortality rate where over a third of sufferers die, and many of the 
survivors experience complications such as brain damage due to prolonged oxygen 
deprivation3,4.  The etiology and pathology of the disease are not fully understood and 
there is a paucity of unique and effective therapies. ARDS is estimated to have an age-
adjusted incidence of 86.2 new cases per 100,000 person-years in adults age 15 and older 
and the total number of cases estimated to occur yearly in the US is about 190,0003. 
It is recognized that ARDS is caused by a complex interplay between multiple 
genetic and environmental factors, yet few advances in prevention and reduction of 
mortality and morbidity have been made3,5-7.  It has recently been shown that complex 
diseases can be between 50 and 90% genetically determined8.  Sepsis is the leading cause 
of ARDS, followed by elective surgery, pulmonary infection, trauma, and other causes9. 
The disease remains in need of specific and efficient preventative measures and 
treatments that can be developed using genetic investigation to identify novel biomarkers 
and treatment targets.  
With the development of next-generation sequencing technologies and 
improvements in data analysis capabilities, it is now feasible to sequence and analyze 
whole genomes in a couple of days10.  However, the cost for whole genome sequencing is 
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still a prohibitive factor for sequencing many samples. Whole exome sequencing (WES) 
is faster and less expensive, making it ideal for the study of variants that cause structural 
changes as candidate gene mutants to human diseases11.  WES is used to study both 
mendelian and complex diseases.   Complex diseases, such as ARDS, can arise in 
populations that are genetically very heterogeneous.  This makes complex diseases 
difficult to predict and treat, necessitating the use of more complex genetic studies, such 
as association studies and linkage analyses12,13.  In the study of ARDS it becomes 
important to take into account the make-up of the study populations.  In our study, 
ethnicity, presence of pneumonia and presence of sepsis are all considered in the 
association analyses. 
The advancements in sequencing technology have created a need for increased 
bioinformatics and data analysis.   Genome-wide association studies (GWAS) are used to 
quantify the association of genetic variations and phenotypes in populations. This data 
analysis technique was developed in response to the increasing volume of genomic data 
in 20056,14.   Genetic association studies compare the association of genotype frequencies 
and specific traits between the case and control populations12,15,16.   Whole exome 
sequence analysis can be applied to perform whole exome wide association studies to 
focus on the identification of coding SNPs associated with human diseases.  By pursuing 
SNPs that are above a threshold of significance and are suspected to have structural 
effects, it becomes possible to pare down the list of candidate variants.  By comparing 
our patient population to the freely available, healthy 1000 Genomes Project control 
genomes and to the different stages of diseases, we will be able to identify SNPs 
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associated with ARDS susceptibility, severity and outcome, which will be determined 
using linear and logistic regressions of patient data, respectively17.   
 4 
 
CHAPTER 2  
REVIEW OF THE LITERATURE 
 
A primary goal of SNP target identification is to identify biomarkers for diagnosis 
and treatment.  ARDS Biomarkers that have been previously studied that are present in 
blood serum include surfactant-associated proteins (SP-A, B, and C), Mucin-associated 
antigens (KL-6 and MUC1), Cytokines (IL-1, 2, 6, 8, 10, and 15, TNF)endothelium 
activation markers (E,L selectim, I-CAM-1, V-CAM-1, and VWF), and neutrophil 
activation markers (MMP-9, LTB4, and Ferritin).  Cytokine levels have been identified 
as a moderately effective measure of severity17.  Other biomarkers of ARDS severity that 
can be obtained from breath include hydrogen peroxide, acidity of the breath18. Despite 
the identification of these biomarkers, their diagnostic capabilities are inconsistent and 
limited The mortality rate of ARDS remain high, especially the mortality of cases with 
common comorbidities sepsis with suspected pulmonary source (40.6%) and witnessed 
aspiration(43.6%) 19.  This warrants that further research be conducted to identify novel 
genetic targets for ARDS prevention and management.   
One of the recently characterized biomarkers of ARDS is Pre-B cell Colony 
Enhancing Factor (PBEF).  Dr. Shui Qing Ye’s group identified several SNPs in the 
human PBEF gene promoter that affect the function of the PBEF gene. They reported 
PBEF was a novel biomarker for ARDS20,21. Their research surrounding the effect of the 
two PBEF promoter polymorphisms suggest that the -1535T (originally labeled as -
1543T) variant allele is associated with a decreased susceptibility to ALI/ARDS and a 
better outcome in septic patients in a Caucasian population when compared with patients 
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without the variation.  The -1001G variant allele was associated with increased 
susceptibility to acute lung injury and ARDS in African American and Caucasian 
populations.  The -1001G variant is also associated with a higher ICU mortality rate in 
septic patients in a Caucasian population22-25.   
 However, it is increasingly recognized that ARDS is a complex disease with 
multiple genetic components that warrant further study.  The lack of currently identified 
biomarkers that have consistently effective application in predicting ARDS susceptibility 
and progression is the fundamental basis for our study, where the ultimate goal is to 
connect the dots between genetics and ARDS outcome.  With current NGS technology, it 
is possible to conduct whole exome sequencing of a sample population and validate the 
population in a secondary or separate population or data. This data can be used to identify 
new diagnostic and therapeutic targets. Genotyping of selected SNPs in an additional 
population can confirm the findings of candidate SNPs.   
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CHAPTER 3 
RESEARCH QUESTION 
 
The purpose of this study is to discover new candidate genes for ARDS risk 
assessment, diagnosis, and treatment.  The identification and validation of new 
biomarkers hold promise for mechanistic insights and novel therapeutic targets. To 
accomplish this, whole-exome sequencing had been performed with the intent of 
identifying coding single nucleotide polymorphisms (SNPs) whose minor allele 
frequencies are significantly different in ARDS than those of healthy controls.  
 
Aim 1: Whole-Exome Association  
 
Using SNP analysis of whole exome sequence data from an ARDS patient 
population and normal healthy controls from Coriell and the 1000 Genomes Project, it 
was possible to identify coding SNPs associated with ARDS susceptibility.   
 
Aim 2: Further Measures of Association and SNP Effects 
 
Regressions of selected SNPs within the patient population were used to assess 
association with severity and outcome.  Functional effect predictions of the SNPs were 
obtained to substantiate potential causality.   
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Aim 3: Validate Selected SNPs in a Larger Patient Population 
 
These data were used to choose candidate SNPs for further validation in a larger 
patient population using genotyping.  Genetic association analysis was performed to 
determine associations between the SNPs and ARDS susceptibility, severity and 
outcome.  Exome sequencing of 96 patient DNA samples from the ARDSnet was 
performed using Illumina's HiScanSQ system. Using these data and the 1000 Genomes 
Project we identified a number of SNPs which are potentially associated with ARDS. 
This study validates three SNPs (rs78142040, rs9605146 and rs3848719) in an additional 
117 ARDS patients for a total of 2013 cases using TaqMan genotyping assays (Life 
Technologies) to substantiate their associations with the susceptibility, severity and 
outcome of ARDS.    
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CHAPTER 4 
METHODOLGY 
 
Sampling 
 
 To perform this case-control study, we used information from DNA samples 
obtained from various study groups (table 1) and from the 1000 Genomes Project.  Data 
on ARDS cases was derived from a 213-participant population obtained from the NHLBI 
ARDS network 05: Fluid and Catheter Treatment Trial26,27.  Phenotype information for 
this population was collected from the Biologic Specimen and Data Repository 
Information Coordinating Center (BioLINCC, http://biolincc.nhlbi.nih.gov.home/). 
Exome sequencing was performed on 96 cases using HiScanSQ (Illumina, CA, USA) in 
the Core of Genetic Research directed by Dr. Shui Qing Ye.  TaqMan genotyping of 
selected candidate SNPs were performed on the remaining 117 patients. 
These data were compared with 625 European Ancestry (EUR) and African 
Ancestry (AFR) samples from the 1000 Genomes Project.  1000 Genome data includes 
genomic context, population genetics, flanking sequence, and any synonyms used in 
publication.  The 1000 Genomes Project AFR population (n=246, 46.8% male) was used 
as a control population for the African American ARDS samples and the EUR population 
(n=379, 47.0% male) will be used as a control for the Caucasian ARDS population. The 
data identifies about 15 million SNPs28.  Descriptors of the ARDS case data include race, 
gender, ARDS etiology (sepsis or pneumonia), ventilator-free days per 28 days after 
admission, APACHE II scores and 60 day mortality (table 1). 
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Table 1: Participant Demographics and comorbidities for the ARDS Cases 
Whole-exome Sequencing Sample group  Participants* Gender 
(%male) 
Age± SD APACHE II score 
±SD 
Ventilator-free 
days per 28 days 
±SD 
60-day mortality (% 
dead at 60 days 
post-onset) 
ARDS total 96 46.9 50±14.6 97.2±30.4 12.6±10.2 29.4 
Caucasian ARDs 70 44.3 50.7±13.8 94.5±30.2 13.6±10.0 23.9 
African American ARDS 26 53.8 47.8±16.6 104.6±30.2 9.9±10.5 44 
ARDS with Sepsis total 48 50 52.0±15.1 105.2±32.2 10.2±10.1 38.3 
Caucasian ARDS with Sepsis 37 43.2 51.8±15.0 102.6±31.1 10.5±9.8 33.3 
African American ARDS with Sepsis 11 72.7 52.9±16.1 113.6±35.8 9.3±11.7 54.5 
ARDS with Pneumonia total 48 43.8 47.9±13.9 88.9±26.2 14.9±9.87 20 
Caucasian ARDS with Pneumonia 33 45.5 49.5±12.4 85.0±26.6 17.0±9.2 12.9 
African American ARDS with Pneumonia 15 40 44.1±16.6 97.6±24.0 10.3±10.0 35.7 
TaqMan Genotyping Sample group Participants Gender 
(%male) 
Age± SD APACHE II score 
±SD 
Ventilator-free 
days per 28 days 
±SD 
60-day mortality (% 
dead at 60 days 
post-onset) 
ARDS Total 117 46.2 50.8±16.6 105.1±32.7 12.0±10.5 31 
Caucasian ARDs 75 40 52.1±15.4 104.3±31.4 11.8±10.5 29.2 
African American ARDS 17 64.7 51.6±22.8 113.3±33.8 12.2±10.6 29.4 
Other ancestry ARDS 25 52 46.4±15.3 101.8±36.2 12.6±10.7 37.5 
ARDS with Sepsis total 59 52.5 51.5±17.3 112.9±31.5 11.3±11.0 37.9 
Caucasian ARDS with Sepsis 34 50 51.1±15.6 113.6±29.7 10.9±11.1 33.3 
African American ARDS with Sepsis 9 66.7 56.6±27.1 121.8±33.0 12.9±11.5 33.3 
Other ancestry ARDS with Sepsis 16 50 49.6±14.8 106.4±34.7 11.4±11.0 50 
ARDS with Pneumonia total 58 39.7 50.1±16.0 96.9±32.3 12.7±9.9 23.6 
Caucasian ARDS with Pneumonia 41 31.7 52.9±15.3 96.4±31.0 12.6±10.0 25.6 
African American ARDS with Pneumonia 8 62.5 46±16.9 103.8±34.3 11.4±10.2 25 
Other ancestry ARDS with Pneumonia 9 55.6 46.8±15.2 92.4±39.7 14.9±10.3 12.5 
Total ARDS Participants Gender 
(%male) 
Age± SD APACHE II score 
±SD 
Ventilator-free 
days per 28 days 
±SD 
60-day mortality (% 
dead at 60 days 
post-onset) 
All ARDS patients 213 46.5 50.4± 15.7 101.6± 31.9 12.3± 10.3 30.2 
*, 8 samples, 4 exome sequenced and 4 TaqMan genotyped ARDS patients did not have these phenotypes available.  An additional 2 
exome sequenced ARDS patients did not have ventilator-free days data.  In addition to the 8 patients missing severity and mortality 
phenotype data, 2 patients were excluded from the regression   
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Ultimately, SNPs that had the largest impact on the susceptibility, severity and 
outcome were picked up for validation.  Measures of ARDS severity include the number 
of ventilator-free days per 28 days (an indication of a patient’s ability to breathe on their 
own) and the APACHE II score (a measure of the severity of a disease in adult patients).  
ARDS outcome is measured by 60 day mortality.  These measures are compared with the 
SNP genotype frequency and participant population to determine the presence of 
correlations. 
 
Research Design 
 
The exome sequence libraries of the NHLBI ARDS samples and the Coriell 
normal controls were created using an Illumina HiScanSQ platform.  Prior to sequencing, 
the DNA was prepared using the TrueSeq Exome Enrichment Kit 
(http://www.illumina.com).  Paired-end sequencing with 101 base pair read lengths was 
preformed, providing a minimum average coverage depth of 50 ×.   
Consensus Assessment of Sequence And variations (CASAVA) software was 
used for the conversion of .bcl files to .fastq format and for demultiplexing 
(http://www.illumina.com).  The sequences were aligned to the hg19 human reference 
genome and variants alleles were called using the Genome Analysis Toolkit 
(http://www.broadinstitute.org/gatk/).  Both the lab-processed ARDS patient samples and 
the 1000 Genomes Project controls were processed using the GATK methodology (figure 
1)22. 
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Figure 1:  The Steps of Next-Generation DNA Sequence Analysis. 
 
GATK was also used to generate the list of SNPs from the sequence data and 
match the SNPs in the sample population to their identifying rs number if one was 
available.  Genotypes of the patient samples were considered to be high-confidence if the 
Phred-like quality was a minimum of 20 and there were at least 4× coverage depths.  The 
exome sequence was chosen rather than the whole genome because it is more likely that 
variants causing structural changes will be observed in exon sequence and the cost and 
time are greatly reduced from whole genome sequencing29.   
 
Analysis 
 
SNP Filtering and Susceptibility Association Test 
The SNP analysis was done in several steps using SNP & Variation Suite v8.1.0 
(Golden Helix, Inc., Bozeman, MT, www.goldenhelix.com). The SNP associations were 
measured by comparing the following groups as listed in Table 3.  By comparing the SNP 
frequencies of smaller subsets of the data it is possible to identify relationships that could 
be obscured in the admixed data set (table 2). 
Workflow of Next-Generation Sequencing data analysis: 
Sequencing 
↓ 
Aligning 
↓ 
Call variants 
↓ 
Filter variants 
↓ 
Biological Interpretation 
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Table 2:  The Comparison Groups for Genetic Association Analysis.   
Exome Seq Cases Secondary Controls 
96 Cases ARDS: whole exome sequenced 
group 
 
625 1000 Genomes Controls 
Cases stratified by race 1000 Genomes Controls stratified by race 
Cases stratified by ARDS etiology (Sepsis or 
Pneumonia) 
 
625 1000Genomes Controls 
Cases stratified by population and ARDS 
etiology (Sepsis or Pneumonia ) 
1000 Genomes Controls stratified by Race 
 
 
To conduct the statistical analyses the ARDS population VCF files were imported 
to SNP & Variation Suite 8 (SVS V8.1.0).  The 1000 genomes exome sequence data was 
provided by Golden Helix in a *.dsf file.  These files and their phenotype data was joined 
and used to calculate the 2 values and 2 p-values for the SNPs that were matched by 
location in SVS V8.1.0 using a basic allelic statistical model.  Calculations were also 
stratified by ancestry and ARDS comorbidity (sepsis and pneumonia).  1,382,399 SNPs 
were identified in the ARDS patients and 714,071 SNPs were available from the 1000 
Genomes Project.  The Bonferroni corrected p-value was determined to be 2.95x10-7 
because 169,376 SNPs were matched between the 1000 Genomes data and the ARDS 
patient data (figure 2).   
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Figure 2:  Pipeline of the exome-seq data analysis workflow.  After 
processing the data using the GATK pipeline, this filtering workflow was 
derived to identify SNPs which were associated with measures of 
susceptibility across the racial and etiology groups of cases.  SNPs were 
filtered based on strength of association, coding effect, and functional 
prediction prior to testing for association with other ARDS phenotypes.   
*, The sample contains African American and Caucasian patients, so the 
EUR and AFR healthy controls from 1000 Genomes were used for 
comparison; **, In the 1000 Genomes Project exome sequence, the same 
714, 074 SNPs are present for all 625 EUR and AFR; §, HWE=Hardy 
Weinberg Equilibrium, p>0.0001; Ɨ, African American with pneumonia, 
African American with Sepsis,  Caucasian with pneumonia, Caucasian 
with sepsis; Ɨ Ɨ, χ2 test of ARDS vs. respective 1000 Genomes Project 
control groups; ǂ, SNPs with P-value <0.01 in the overall comparison, 
Caucasian ARDS comparison, and African American comparison with 
1000 Genomes were filtered further by p<0.01 in the Sepsis comparison 
and Pneumonia comparison; ǂ ǂ, All ARDS cases, all pneumonia cases, all 
sepsis cases, all African American cases, all Caucasian cases. 
 
SNPs that were present in all 4 of the ARDS sub populations Caucasians with 
sepsis, Caucasians with pneumonia, African Americans with sepsis, and African 
Americans with pneumonia were selected for the statistical association tests, totaling 
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49,789 (table 3).  SNPs with a chi square p-value smaller than the Bonferroni-corrected 
p-value in at least 2 of the 5 main populations (All ARDS vs. 1000 Genomes, All Sepsis 
vs. 1000 Genomes, All Pneumonia vs. 1000 Genomes, African American ARDS vs. AFR 
1000 Genomes, and Caucasian ARDS vs. EUR 1000 Genomes) were considered 
further23,24.   The 2 test of the categorical data was used to identify novel targets for 
study. This was represented graphically by Manhattan plots generated using SVS v7.8.  
Hardy-Weinberg equilibrium and SNP call rate were calculated using the Marker 
Statistics feature of SVS V8.1.0.  SNPs were considered to be in HWE if the p-value was 
>1×10-4.  The call rate of the 1000 genomes project controls was 100%, meaning there 
were no missing genotypes.  The call rate of the ARDS SNPs was considered to be good 
if it was >95% in the total exome sequenced population17,30-37.  
 
 
Table 3:   The Populations and Subpopulations Used for Analyses   
Population SNPs Called (SVS) X2 test compared with: 
SNPs matched 
by location in 
SVS exome 
AA pneumonia 629,987 AA 1000 Genomes 108,180 
AA sepsis 533,174 AA 1000 Genomes 95,917 
EA pneumonia 748,096 EA 1000 Genomes 94,039 
EA sepsis 769,702 EA 1000 Genomes 89,380 
All ARDS* 272,963 (1,382,399) 1000 Genomes 50,190 
All sepsis* 324,514 (978,362) 1000 Genomes 57,247 
All pneumonia* 365,324 (1,012,760) 1000 Genomes 63,755 
All EA ARDS* 473,138 (1,044,661) EA 1000 Genomes 74,359 
All AA ARDS* 383,188 (779,973) AA 1000 Genomes 75,120 
1000 Genomes Project 714,071 NA NA 
1000 Genomes Project AA 714,071 NA NA 
1000 Genomes Project EA 714,071 NA NA 
*= SNPs common across included subgrous, followed by (all detected).  Only 
SNPs that were in all subgroups were included in the X2 tests for association with 
case-control status.  **The same ARDS populations were used for the regressions 
against ARDS phenotypes.  Chi-square tests were run on SNPs that were in both 
the controls and the cases.   
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Regressions with Comorbidities Among ARDS Cases 
The next phase of the data analysis was to investigate the association of candidate 
SNPs in the exome sequence with ARDS severity and outcome.  The analyses were 
conducted using numerically coded genotypes in an additive model.  The frequencies of 
the genotypes of the SNPs were compared with the APACHE II score using a linear 
regression and the APACHE II score quartiles 1 and 4 using a logistic regression.  The 
genotypes were also compared using a linear regression of ventilator free days.  The 
logistic regression of genotype vs. 60 day mortality will provide a measure of relationship 
between the SNP and the outcome.  The significance level for these test were set at 
p<0.05 for the logistic regressions and R2 >0.8 for the linear regressions.  All regressions 
were run on the overall population as well as the subpopulations with the exception of the 
APACHE II 1st quartile versus 4th quartile regression, which was only run on the All 
ARDS group.  In addition to the 8 patients missing severity and mortality phenotype data, 
2 patients were excluded from the regression because their phenotypes were missing at 
the moment of the analysis.  These same statistics were repeated for the TaqMan 
genotyped patients (117 patients) and the total population (213 patients) when the 
candidate SNPs were chosen and genotyped further down the workflow. 
Variant analysis and Functional Effect Predictions 
Following the results of the genetic association study the data was further 
analyzed by Variant Analysis component of SVS V8.1.0.  This software ranked the SNPs 
in order of likely importance based on location as well as make amino acid change 
predictions.  This information was joined with predictions of protein functional effect 
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changes made by Sift and Provean (http://provean.jcvi.org/index.php) as well as 
Polyphen2 (http://genetics.bwh.harvard.edu/pph2/index.shtml).   
Pathway Analysis 
Ingenuity® Pathway Analysis™ Software (www.ingenuity.com/) from Ingenuity 
Systems was used to screen for SNPs which are likely to alter the function of relevant 
biologic pathways.  To accomplish this I submitted a list of the genes that contain SNPs 
with  2 p-value of <0.01 in the 5 main comparisons of exome sequence data (All ARDS 
vs. 1000 Genomes, All sepsis vs. 1000 Genomes, All pneumonia vs. 1000 Genomes, 
African American ARDS vs. AFR 1000 Genomes, and Caucasian ARDS vs. EUR 1000 
Genomes).    
Assessment of Population Structure 
Quantile-quantile plots (QQ plots) are used to visualize skew in data distributions 
between the transformed expected p-values or χ2 values of a test and the actual p-values 
or χ2 values of the test.  In a QQ plot, the expected and actual values are expected to 
approximate a line of X=Y when plotted against each other37.  Population structure 
differences between the ARDS exome sequenced patients and the 1000 Genomes healthy 
controls are visualized using QQ plots of the trend test χ2 values and by computing the 
principal components using the Eigensoft PCA method in SVS for the All ARDS and All 
1000 Genomes group, Caucasian ARDS and EUR 1000 Genomes subgroup, and African 
American ARDS and AFR 1000 Genomes subgroup37.    
Principal component analysis (PCA) is used to identify the components that 
contribute to genetic structure in a dataset.  Principal components (PCs) that have a large 
contribution to the population structure can be corrected for in association tests to adjust 
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for genetic variability that isn’t related to the exposure of interest.   The data for the 
ARDS and the ancestry subgroups was filtered to include the SNPs that were considered 
to be in Hardy-Weinberg Equilibrium (HWE) in the 1000 Genomes project controls 
(HWE p-value >1x10^04), in linkage equilibrium in the ARDS+1000 Genomes 
populations (pairwise R2>0.2 in a 200 SNP window moving in 25 SNP increments), and 
have a good call rate (>0.95 in the ARDS+1000 Genomes populations) per SNP.  Sample 
call rate was not used in filtering due to the small population size. SNPs in chromosomes 
1-X were used to determine principal components (eigenvalues).  The maximum number 
of principal components is equal to the number of study participants, so N-1 principal 
components were calculated for the total population and the 2 racial subpopulations.  The 
largest eigenvalues calculated using PCA were corrected for in a genotype trend test.  
The cutoff for correction was determined using Scree plots and the regression with cases-
control status, where the PCs with the largest eigenvalues down to the point where the p-
values were no longer significant (p<0.001) were corrected in the trend tests.  Outlying 
samples were identified as being more than 6 SD away from the number of PCs chosen 
for correction in a genotype trend test and the PCs were recomputed 5 times37.  PC 
corrected trend tests and PC and outlier corrected trend tests were run with correction for 
9 components for the All ARDS and 1000 Genomes group, 6 components for the 
Caucasian ARDS and EA 1000 Genomes subgroup, and both 2 and 20 components for 
the AA ARDS and AA 1000 Genomes subgroup).    
The genomic inflation factors () were calculated for the trend test for the 
unfiltered exome cases vs. controls, filtered but pre-PCA data, and PCA corrected data to 
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quantify the amount of error that could be attributed to population stratification or 
sequencing error37.   
 
Genotyping of Selected Candidates 
 
These data were compiled and used to determine the top SNP candidates using the 
criteria that they were present in all 4 individual ARDS populations (African American 
Sepsis, African American Pneumonia, Caucasian Sepsis, and Caucasian Pneumonia), had 
a 2 p-value < 0.01 in the 5 main ARDS populations, had a 2 <2.95x10-7 in at least 2 of 
the 5 main populations, and had some association with severity or outcome.  Functional 
prediction information was also taken into account, and nonsynonymous SNPs were 
preferred because of their likelihood of causing direct functional effects. 
Ultimately, three SNPs (rs78142040; rs9605146, also known as rs114989947; and 
rs3848719) in the additional 117 ARDS patient DNA samples from the NHLBI 
ARDSNet were genotyped using TaqMan human SNP genotyping assays on the ViiA 7 
machine (http://www.invitrogen.com/ )  according to the supplier’s instruction (Life 
Technologies).Using the sequence we provided, the first allele is detected using a VIC 
dye probe and the second allele is detected using a FAM dye probe. The sample DNA 
undergoes PCR amplification, using an output of the allele calls for each sample, the 
genotypes can be identified and analyzed.   The genotype data from ARDS patients were 
compared with the genotype frequency calculated from the population genetics available 
for the SNPs from the 1000 Genomes Project37.  Genotyping by the TaqMan assay is fast 
and targeted, making it the ideal tool for confirming SNP frequencies.   Genotyping 
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accuracy was confirmed using the reference samples in-lab.  Genotyping data from the 
additional samples was used to validate the associations observed in the ARDS vs. 1000 
Genomes comparisons by calculating the association statistics described above.   
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CHAPTER 5 
RESULTS 
 
Whole-Exome Sequencing and Identification of SNPs Associated With Susceptibility 
 
The overall study population included 625 genome-sequenced controls from the 
1000 Genomes Project and 213 ARDS patients (96 exome-sequenced patients and 117 
patients genotyped for the 3 specific SNPs).  These patients consist of 70 Caucasian and 
26 African-Americans (table 1). In Caucasian patients, 37 cases were due to the initiating 
etiology of sepsis and 33 were due to pneumonia. In African American patients, 11 cases 
were due to the initiating etiology of sepsis and 15 were due to pneumonia. We detected 
1,382,399 SNPs in 96 ARDS patients by exome-seq (table 4) and 490,015 SNPs per 
person on average. Among them, 169,376 SNPs matched records from the 625 healthy 
control subjects in the 1000 Genomes Project. From the 169,376 SNPs, there are 49,789 
bi-allelic SNPs(50,190 total) in all ARDS patient subgroups based on race and initiating 
etiologies: Caucasian sepsis, Caucasian pneumonia, African-American sepsis and African 
American pneumonia (figure 3).   
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Figure 3:  Manhattan Plot of ARDS Patients and 1000 Genomes Project Controls. 
 
 (A)A Manhattan plot of the whole exome sequence all ARDS cases vs. the 1000 
Genomes Project controls created using SVS v8.1.0.   This is a graphic 
representation of the chromosome location (x axis) vs. the –log10 (2 p-value) of 
the allele frequencies.  SNPs whose chi-square tests yield a smaller p-value fall 
higher on the log scale are more significant37.  (B) The same Manhattan plot with 
a zoomed Y-axis. 
 
Of our 1,382,399 ARDS SNPs, 608,723 were common between the sepsis and 
pneumonia cases (369,639 and 404,037 non-overlapping SNPs, respectively) and 
442,235 SNPs were common between our African American cases and Caucasian cases 
(337,738 and 602,426 non-overlapping SNPs, respectively).  85.4% of the 1,213,023 
ARDS SNPs not found in the 1000 Genomes Project Exome were assigned RS numbers, 
suggesting our data collection and processing is reliable.  
By comparing the frequencies of the minor alleles in those SNPs in our 96 ARDS 
patients with 625 Caucasian and African-American healthy control subjects of the 1000 
human genome project, we found that  there are 3,867 differential SNPs (chi-square test 
ARDS vs. 1000 Genomes Project  
ARDS vs. 1000 Genomes Project 
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p<0.01ƗƗ). In Caucasians between ARDS patients and healthy controls, there are 788 
differential SNPs (p<0.01ƗƗ). In African-Americans between ARDS patients and healthy 
controls, there are 1,203 differential SNPs (p<0.01ƗƗ). There are 208 common differential 
SNPs (p<0.01) in both Caucasian and African American patients or healthy controls. 
When we separately examined sepsis- or pneumonia-initiated ARDS, we found that 195 
and 184 differential SNPs (p<0.01), respectively. Between them, there are 171 common 
differential SNPs (p<0.01). When the Bonferroni correction (p<2.95x10-7) was applied, 
89 SNPs remains significantly different. These SNPs are potentially novel coding SNPs 
associated with the ARDS susceptibility. Functional prediction information was also 
taken into account, and nonsynonymous SNPs were focused because of their likelihood 
of causing direct functional effects (table 4).   
 
Table 4: Summary of the Filtering Applied to Candidate SNPs  
Criteria for filtering Number of remaining variants 
SNPs detected in ARDS SNPs 1,382,399 
matched in 1000 Genomes Project 169,376 
common across 4 ARDS race and etiology 
groups* 50,190 
χ² p-value <0.01 in top 5 ARDS groups** 171 
χ² p-value <2.95x10-7 in at least 2/5 top 5 
ARDS groups 89 ( in 76 genes) 
coding variants 49 (in 38 genes) 
nonsynonymous and splice variants 23 
synonymous variants 26 
*, African American with pneumonia, African American with Sepsis, Caucasian with 
pneumonia, Caucasian with sepsis subgroups.  Out of the 50, 190 SNPs, 49,789 are bi-
allelic.  **, All ARDS, all pneumonia, all sepsis, all African American, all Caucasian 
groups 
 
Of these SNPs 89 have a 2 p-value of <2.95x10^07 in at least 2 of the 5 main 
populations.   49 of these are expected to be in coding regions of the DNA.  Of these, 22 
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cause nonsynonymous amino acid coding changes, 26 cause synonymous coding 
changes, 1is a splicing variant, and 1 was indeterminate (presumed to be intronic).  
Regressions with ARDS severity and mortality phenotypes were performed on 25 SNPs 
including the 22 nonsynonymous SNPs, 1 splice variant, 1 of the synonymous SNPs, and 
1 unknown (presumed intronic) SNP.   
 
Pathway Analysis 
 
Ingenuity pathway analysis was conducted on the 76 genes that contain the top 89 
SNPs to identify biologic pathways in which these genes function.  The top canonical 
pathway is Nur77 signaling in T Lymphocytes and included 5 genes that contained 
associated SNPs, comprising 8% of the genes involved in the pathway (p=1.47x10-6) 
(table 5).   
 
 Table 5: Top Canonical Pathways of Genes Containing SNPs Associated with ARDS. 
Top Canonical Pathways p-value* Ratio** Molecules 
Nur77 Signaling in T 
Lymphocytes 
1.47x10-6 0.08 CASP9,HLA-DQA1,HLA-
DRB1,HLA-DQB1,SIN3A 
Calcium-induced T 
Lymphocyte Apoptosis 
6.93x10-5 0.06 HLA-DQA1,HLA-DRB1,HLA-
DQB1,ITPR1 
B Cell Development 1.97x10-4 0.08 HLA-DQA1,HLA-DRB1,HLA-
DQB1 
iCOS-iCOSL Signaling 
in T Helper Cells 
5.69x10-4 0.03 HLA-DQA1,HLA-DRB1,HLA-
DQB1,ITPR1 
Graft-versus-Host 
Disease Signaling 
5.82x10-4 0.03 CASP9,HLA-DQA1,HLA-
DRB1,HLA-DQB1 
Top canonical pathways as predicted from the 76 genes containing the 89 SNPs that 
were identified using 2 tests.   Pathway predictions were done using the Core Analysis 
function of Ingenuity Pathway Analysis.     
*, P-Value of <0.05 indicates a non-random association between the genes and 
pathway  
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**, Ratio of the number of genes in the dataset involved in the pathway to the total 
number of genes in the pathway 
 
 
The top 5 canonical pathways additionally include calcium-induced T-lymphocyte 
signaling, B-cell development, iCOS-iCOSL signaling in T helper cells, and graft-versus-
host disease signaling.   
 
Validation of 3 SNPs 
 
3 SNPs (rs78142040, rs9605146, and rs3848719) were genotyped in a larger 
population and statistics were re-computed (table 6). 
 
Table 6: Overall association summary 
   rs3848719 rs9605146 rs78142040 
Susceptibility (cases vs. controls)    
Chi-squared p-value  9.39E-5 8.64E-71 6.68E-61 
Odds Ratio (95% CI)1  1.61(1.27-2.05) 12.90(9.29-17.93) 87.76(32.00-240.65) 
Severity  
(ventilator-free days/28 days)    
p-value  NS NS NS 
Odds Ratio (95% CI)2  NS NS NS 
Severity (APACHE II score)    
p-value  0.032 NS 0.061** 
Odds Ratio (95% CI)2  0.55 (0.31-0.96) NS 2.60(0.93-7.26) 
Outcome  
(60-day mortality)    
p-value  NS* NS 0.017 
Odds Ratio (95% CI)2  NS NS 2.04 (1.13-3.68) 
NS, Not significant; * significantly associated in genotyped Caucasian, pneumonia, and 
Caucasian pneumonia subgroups; **, genotyped samples only; 1, Odds ratio for alternate 
allele (allelic test); 2, additive genotypic model 
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Rs78142040 has a major allele C and a minor allele T and is found on the X 
chromosome position X:2832771 in the Arylsulfatase D gene (ARSD). The SNP we have 
identified is significantly associated with susceptibility (p<2.95x10^-7) in the total 213 
patient population (MAF=0.22) and the subgroups when compared with controls from the 
1000 genomes project (MAF=0.003) (tables 7, 8).   
 
Table 7: rs78142040 Statistics. 
SNP rs78142040 
position X:2832771 
Gene (s) ARSD 
 96 Exome 117 TaqMan Total 213 
2 P-value* 1.14E-50 2.26E-62 6.68E-61 
2 224.13 277.51 271.06 
Odds Ratio (Alternate Allele) 77.88 95.71 87.76 
OR Lower Confidence Bound (Alt.) 27.32 34.27 32.00 
OR Upper Confidence Bound (Alt.) 221.94 267.30 240.65 
Call Rate 0.99 1.00 0.99 
Call Rate (Cases) 0.94 1.00 0.97 
HWE P-value (Cases) 1.77E-2 2.17E-2 1.18E-3 
HWE P-value (Controls) 6.11E-138 6.11E-138 6.11E-138 
HWE P-value 4.75E-2 6.56E-3 4.07E-1 
Number of Distinct Alleles 2 2 2 
Alternate Allele T T T 
Alternate Allele Frequency 0.03 0.04 0.06 
Alt. Allele Freq. (Cases) 0.20 0.24 0.22 
Alt. Allele Freq. (Controls) 0.003 0.003 0.003 
Reference Allele C C C 
Reference Allele Frequency 0.97 0.96 0.94 
Ref. Allele Freq. (Cases) 0.80 0.76 0.78 
Ref. Allele Freq. (Controls) 0.997 0.997 0.997 
Genotype AA Count    
AA (Cases) 0 2 2 
AA (Controls) 2 2 2 
Genotype Ar Count 36 51 87 
Ar (Cases) 36 51 87 
Ar (Controls) 0 0 0 
Genotype rr 677 687 741 
rr  (Cases) 54 64 118 
rr (Controls) 623 623 623 
Alternate Allele A Count 40 59 95 
A (Cases) 36 55 91 
A (Controls) 4 4 4 
Reference Allele r 1390 1425 1569 
r (Cases) 144 179 323 
r (Controls) 1246 1246 1246 
A summary of the SNP rs78142040 in the exome sequenced ARDS, TaqMan 
genotyped ARDS patients, and total ARDS patients, where the controls are 
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1000 Genomes Project participants.  “A” represents the alternate allele and “r” 
represents the reference allele.   
*, Chi-square tests were run on SNPs that were in both the controls and the 
cases.   
 
 
 
Table 8: Chi-Square Test P-Values for rs78142040 in Patients and Controls. 
SNP rs78142040 
Gene ARSD 
 96 Exome 117 TaqMan Total 213 
ARDS 2 P-value    
Caucasian 2 P-value 1.14E-50 2.16E-62 6.68E-61 
African American 2 P-value 8.59E-32 8.65E-35 4.30E-34 
Pneumonia 2 P-value 2.14E-22 1.18E-26 7.97E-28 
Sepsis 2 P-value 4.10E-33 1.55E-42 1.71E-42 
African American Sepsis 2 P-value 4.20E-59 1.81E-72 3.15E-72 
African American Pneumonia 2 P-value 3.30E-27 1.46E-22 1.31E-30 
Caucasian Sepsis 2 P-value 1.73E-11 1.06E-19 2.50E-18 
Caucasian Pneumonia 2 P-value 1.88E-37 1.60E-46 9.85E-43 
The allelic chi-square test p-values for the exome sequenced ARDS patients ARDS patients 
and subgroups compared with the 1000 Genomes Project participants and subgroups, 
TaqMan genotyped ARDS patients and subgroups compared with the 1000 Genomes 
Project participants and subgroups , and the total ARDS patient population and subgroups 
compared with the 1000 Genomes Project participants and subgroups.  P-values were 
considered to be significant if they were smaller than the Bonferroni corrected p-value of 
2.95x10^-7. 
 
 
Rs78142040 approaches association with APACHE II score when the score 
quartiles are compared for the genotyped ARDS patients (p=0.061, OR=2.603, 95% 
CI=0.933-7.260) (table 9).  
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Table 9: Logistic Regression of Genotype and APACHE II Score by 
Quartile. 
SNP rs3848719 rs9605146 rs78142040 
Gene (s) ZNF335 XKR3 ARSD 
Exome samples    
p-value 0.10 0.15 na 
Odds Ratio 0.50 2.00 na 
OR Lower Conf. Bound 0.22 0.76 na 
OR Upper Conf. Bound 1.16 5.26 na 
TaqMan samples    
p-value 0.30 0.36 0.06 
Odds Ratio 0.68 0.70 2.60 
OR Lower Conf. Bound 0.33 0.33 0.93 
OR Upper Conf. Bound 1.42 1.50 7.26 
All samples    
p-value 0.03 0.78 0.29 
Odds Ratio 0.55 1.08 1.51 
OR Lower Conf. Bound 0.31 0.62 0.70 
OR Upper Conf. Bound 0.96 1.89 3.25 
The APACHE II scores are split into quartiles and the 1st and 4th quartiles are 
used in a logistic regression against genotype using an additive model in the 
ARDS exome samples, TaqMan genotyped samples, and total ARDS 
samples.  Regressions were also run on the stratified sub-populations of the 
ARDS patients.  Associations were considered to be significant if P<0.05.   
 
Rs78142040 is associated with the 60-day mortality in the genotyped ARDS 
group (p=0.034, OR=2.245, 95%CI 1.053-4.786), the total ARDS population (p=0.017, 
OR=2.039, 95%CI 1.130-3.681) and the all-sepsis subgroups of the genotyped patients 
and total ARDS population (p=0.029, OR=2.981, 95%CI 1.072-8.289 and p=0.035, 
OR=2.276, 95%CI 1.044-4.961, respectively) (table 10).   
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Table 10: Logistic Regression of Genotype and 60-Day Mortality. 
SNP rs78142040 
Gene (s) ARSD 
 96 Exome 117 TaqMan Total 213 
ARDS p-value 0.2630728 0.0339629 0.0173745 
Pneumonia p-value 0.6602961 0.8575796 0.6581823 
Sepsis p-value 0.5246962 0.028991 0.0348283 
Caucasian p-value 0.2222798 0.9495742 0.408666 
African American p-value 0.8547592 na 0.3606608 
African American Pneumonia p-value 0.9282386 na 0.5363197 
African American Sepsis p-value 0.4870023 na 0.596097 
Caucasian Sepsis p-value 0.373584 0.8254455 0.4565353 
Caucasian Pneumonia p-value 0.8171329 0.6294941 0.7551327 
SNP rs9605146 
Gene (s) XKR3 
 96 Exome 117 TaqMan Total 213 
ARDS p-value 0.199116 0.1613938 0.8628899 
Pneumonia p-value 0.0799541 0.1352877 0.9207455 
Sepsis p-value 0.6639858 0.4980102 0.8681921 
Caucasian p-value 0.676358 0.0857127 0.3488488 
African American p-value 0.2706209 0.4411772 0.6577734 
African American Pneumonia p-value 0.3251523 0.4184522 0.6835628 
African American Sepsis p-value 0.553167 0.7626348 0.7754479 
Caucasian Sepsis p-value 0.9381507 0.258087 0.527152 
Caucasian Pneumonia p-value 0.4336663 0.1939841 0.4733411 
SNP rs3848719 
Gene (s) ZNF335 
 96 Exome 117 TaqMan Total 213 
ARDS p-value 0.2983921 0.3583787 0.9136127 
Pneumonia p-value 0.1851452 0.0323794 0.380281 
Sepsis p-value 0.5992432 0.455294 0.3463909 
Caucasian p-value 0.6700216 0.0122873 0.2039698 
African American p-value 0.9736738 na 0.7412062 
African American Pneumonia p-value 0.9149283 na 0.5810341 
African American Sepsis p-value 0.8580141 na 0.8671714 
Caucasian Sepsis p-value 0.919974 0.306832 0.5617649 
Caucasian Pneumonia p-value 0.2672277 0.011951 0.2015335 
 
The p-values of the logistic regression of 60-day mortality against 
genotype using an additive model in the ARDS exome samples, 
TaqMan genotyped samples, and total ARDS samples.  Regressions 
were also run on the stratified sub-populations of the ARDS patients. 
 
 
The SNP is in Hardy-Weinberg Equilibrium (HWE p>1x10-4) in the EUR 
1000genomes controls and in the ARDS population and subgroups.  The SNP was 
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determined to lie within a histone mark of intron 6 using the UCSC Genome Browser and 
could potentially play a role in regulation of expression (http://genome.ucsc.edu/). 
 
rs9605146 has a major allele G and minor allele A.  It is a nonsynonymous SNP 
found within exon 4 of chromosome 22 (22: 17265194) in the “XK, Kell blood group 
complex subunit-related family, member 3” gene and causes a predicted amino acid 
change from proline to leucine (XKR3).  This amino acid change has a deleterious effect 
predicted by a Provean score of -5.494, where a score of maximum -2.5 is considered to 
be deleterious (table 11).   
 
 
Table 11:  Predicted Effects of the 4 SNPs on Amino Acid Coding. 
dbSNP_ID rs3848719 rs9605146 rs78142040 
Gene (s) ZNF335 XKR3 ARSD 
SNP Classification Coding Coding Coding 
Coding Classification Synonymous Nonsyn SNV Intronic 
Reference amino acid S P NK 
Alternate amino acid S L NK** 
TYPE Synonymous Single AA Change NK 
Provean prediction (cutoff=-25) Neutral Deleterious NK 
Sift prediction (cutoff=0.05) Tolerated Tolerated NK 
Sift, Provean, and Polyphen2 were used to predict the functional changes 
expected to be caused by the SNPs.  *, PolyPhen2; **, Not Known 
 
 
The SNP is in HWE (p>1x10-4) in the EUR 1000 Genomes Project as well as in 
the ARDS population and subgroups.  Rs9605146 is associated with disease 
susceptibility (p<2.95x10^-7) in the total ARDS population (MAF=0.39) and subgroups 
when compared with the 1000 genomes controls (MAF=0.05) (tables 12, 13).  
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Table 12: rs9605146 Statistics. 
SNP rs9605146 
position 22:17265194 
Gene (s) XKR3 
 96 Exome 117 TaqMan Total 213 
2 P-value* 8.37E-58 2.38E-51 8.64E-71 
2 256.84 227.25 316.44 
Odds Ratio (Alternate Allele) 14.52 11.72 12.91 
OR Lower Confidence Bound (Alt.) 9.80 8.06 9.29 
OR Upper Confidence Bound (Alt.) 21.51 17.05 17.93 
Call Rate 1.00 1.00 1.00 
Call Rate (Cases) 0.97 1.00 0.99 
HWE P-value (Cases) 3.78E-1 8.22E-1 4.22E-1 
HWE P-value (Controls) 5.13E-15 5.13E-15 5.13E-15 
HWE P-value 2.35E-21 7.83E-16 4.34E-19 
Number of Distinct Alleles 2 2 2 
Alternate Allele A A A 
Alternate Allele Frequency 0.09 0.10 0.13 
Alt. Allele Freq. (Cases) 0.41 0.36 0.39 
Alt. Allele Freq. (Controls) 0.05 0.05 0.05 
Reference Allele G G G 
Reference Allele Frequency 0.91 0.90 0.87 
Ref. Allele Freq. (Cases) 0.59 0.64 0.61 
Ref. Allele Freq. (Controls) 0.95 0.95 0.95 
Genotype AA Count 28 26 44 
AA (Cases) 18 16 34 
AA (Controls) 10 10 10 
Genotype Ar Count 79 91 132 
Ar (Cases) 41 53 94 
Ar (Controls) 38 38 38 
Genotype rr 611 625 659 
rr  (Cases) 34 48 82 
rr (Controls) 577 577 577 
Alternate Allele A Count 135 143 220 
A (Cases) 77 85 162 
A (Controls) 58 58 58 
Reference Allele r 1301 1341 1450 
r (Cases) 109 149 258 
r (Controls) 1192 1192 1192 
A summary of the SNP rs9605146 in the exome sequenced ARDS, TaqMan 
genotyped ARDS patients, and total ARDS patients, where the controls are 
1000 Genomes Project participants. “A” represents the alternate allele and “r” 
represents the reference allele. 
*, Chi-square tests were run on SNPs that were in both the controls and the 
cases.   
 
Associations with severity and outcome are not statistically significant.  The SNP 
also approaches significant association with 60-day mortality in the exome-sequenced 
patients with pneumonia (p=0.080).   
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Table 13: Chi-Square Test P-Values for rs9605146 in Patients and Controls. 
SNP rs9605146 
Gene XKR3 
 96 Exome 117 TaqMan Total 213 
ARDS 2 P-value 8.37E-58 2.37E-51 8.64E-71 
Caucasian 2 P-value 5.26E-34 7.31E-37 1.19E-44 
African American 2 P-value 1.53E-28 3.81E-13 3.05E-30 
Pneumonia 2 P-value 2.50E-42 9.95E-33 4.55E-53 
Sepsis 2 P-value 9.64E-38 1.12E-39 2.46E-55 
African American Sepsis 2 P-value 1.72E-16 7.96E-8 1.02E-18 
African American Pneumonia 2 P-value 1.66E-21 6.34E-9 7.32E-24 
Caucasian Sepsis 2 P-value 4.71E-25 6.52E-26 4.94E-35 
Caucasian Pneumonia 2 P-value 3.91E-24 2.82E-28 6.46E-36 
The allelic chi-square test p-values for the exome sequenced ARDS patients ARDS patients 
and subgroups compared with the 1000 Genomes Project participants and subgroups, 
TaqMan genotyped ARDS patients and subgroups compared with the 1000 Genomes 
Project participants and subgroups , and the total ARDS patient population and subgroups 
compared with the 1000 Genomes Project participants and subgroups.  P-values were 
considered to be significant if they were smaller than the Bonferroni corrected p-value of 
2.95x10^-7. 
 
rs3848719 is a synonymous SNP in the 5th exon of the Zinc-Finger/Leucine-
Zipper Co-Transducer NIF1 gene in chromosome 20 (location 20: 44596545) (ZNF335).  
The SNP rs3848719 has a major allele of G and a minor allele A.  The SNP approaches 
association with susceptibility (p=9.39x10-5) in the total ARDS population (MAF=0.39) 
and in the exome ARDS subgroup when compared with the 1000 genomes controls 
(MAF=0.29) (table 14, table 15).  
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Table 14: rs3848719 Statistics. 
SNP Rs3848719 
position 20:44596545 
Gene (s) ZNF335 
 96 Exome 117 TaqMan Total 213 
2 P-value* 2.68E-6 9.26E-2 9.39E-5 
2 22.03 2.83 15.25 
Odds Ratio (Alternate Allele) 2.28 1.29 1.61 
OR Lower Confidence Bound (Alt.) 1.61 0.96 1.27 
OR Upper Confidence Bound (Alt.) 3.24 1.73 2.05 
Call Rate 0.97 1.00 0.97 
Call Rate (Cases) 0.74 1.00 0.88 
HWE P-value (Cases) 3.81E-6 5.86E-1 2.86E-4 
HWE P-value (Controls) 4.76E-3 4.76E-3 4.76E-3 
HWE P-value 2.30E-6 4.63E-3 4.90E-6 
Number of Distinct Alleles 2 2 2 
Alternate Allele A A A 
Alternate Allele Frequency 0.31 0.30 0.31 
Alt. Allele Freq. (Cases) 0.48 0.34 0.39 
Alt. Allele Freq. (Controls) 0.29 0.29 0.29 
Reference Allele G G G 
Reference Allele Frequency 0.69 0.70 0.69 
Ref. Allele Freq. (Cases) 0.52 0.66 0.61 
Ref. Allele Freq. (Controls) 0.71 0.71 0.71 
Genotype AA Count 92 81 107 
AA (Cases) 26 15 41 
AA (Controls) 66 66 66 
Genotype Ar Count 243 277 293 
Ar (Cases) 16 50 66 
Ar (Controls) 277 277 277 
Genotype rr 361 384 413 
rr  (Cases) 29 52 81 
rr (Controls) 332 332 332 
Alternate Allele A Count 427 439 507 
A (Cases) 68 80 148 
A (Controls) 359 359 359 
Reference Allele r 965 1045 1119 
r (Cases) 74 154 228 
r (Controls) 891 891 891 
A summary of the SNP rs3848719 in the exome sequenced ARDS, TaqMan 
genotyped ARDS patients, and total ARDS patients, where the controls are 
1000 Genomes Project participants. “A” represents the alternate allele and 
“r” represents the reference allele. 
*, Chi-square tests were run on SNPs that were in both the controls and the 
cases.   
 
 
rs3848719 is also associated with is associated with APACHE II score when the 
score quartiles are compared for total ARDS patients (p=0.032, OR=0.549, 
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95%CI=0.313-0.96).  The SNP is associated with 60-day mortality in the TaqMan 
genotyped Caucasian ARDS (p=0.012, OR=2.753, 95% CI=1.196-6.336), TaqMan 
genotyped pneumonia (p=0.032, OR=2.511, 95% CI=1.053-5.984), and TaqMan 
genotyped Caucasians with pneumonia (p=0.012, OR=4.045, 95% CI=1.219-13.433).   
The SNP is in HWE (p>1x10-4) in the Overall, EUR and AFR 1000 Genomes Project 
groups as well as in the overall ARDS population and subgroups with the exception of 
the combined African American ARDS cases.   
 
Table 15: Chi-Square Test P-Values for Rs3848719 in Patients and Controls. 
SNP rs3848719 
Gene ZNF335 
 96 Exome 117 TaqMan Total 213 
ARDS 2 P-value 2.68E-6 9.26E-2 9.39E-5 
Caucasian 2 P-value 4.24E-3 4.22E-1 2.78E-1 
African American 2 P-value 1.32E-4 6.73E-1 2.68E-3 
Pneumonia 2 P-value 1.26E-3 1.92E-1 4.03E-3 
Sepsis 2 P-value 2.72E-4 2.37E-1 2.26E-3 
African American Sepsis 2 P-value 2.79E-3 2.48E-1 1.55E-1 
African American Pneumonia 2 P-value 6.12E-3 7.29E-2 1.87E-3 
Caucasian Sepsis 2 P-value 3.76E-2 4.58E-1 4.26E-1 
Caucasian Pneumonia 2 P-value 3.57E-2 6.47E-1 3.99E-1 
 
The allelic chi-square test p-values for the exome sequenced ARDS patients ARDS patients 
and subgroups compared with the 1000 Genomes Project participants and subgroups, 
TaqMan genotyped ARDS patients and subgroups compared with the 1000 Genomes 
Project participants and subgroups , and the total ARDS patient population and subgroups 
compared with the 1000 Genomes Project participants and subgroups.  P-values were 
considered to be significant if they were smaller than the Bonferroni corrected p-value of 
2.95x10^-7. 
 
Two of the 3 SNPs selected for further study (rs78142040 and rs3848719) are 
significantly associated with outcome as measured by 60-day mortality in at least one 
subgroup of the ARDS patients (table 10).   
Of the 3 SNPs selected for further study, one SNP (rs3848719) is significantly 
associated with a reduction in severity as measured by a comparison of the highest and 
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lowest APACHE II score quartiles (p<0.05) and one SNP (rs8142040) approaches 
significant association with APACHE II score quartile (table 9).  
 SNPs rs9605146 is predicted by Provean to cause deleterious changes in amino 
acid coding and predicted to cause neutral changes by Sift and Polyphen2.  SNP 
rs3848719 is predicted to have a neutral effect by Sift and Provean, and is not found 
using Polyphen2.  SNP rs78142040 is assumed to be in a non-protein coding region of 
DNA.     
 
Assessment of Population Structure 
 
Genotype trend tests were conducted before filtering, after filtering, after PCA, 
and after PCA with outlier sample removal to visualize the skew in the expected vs. 
actual 2 values of the genotype trend test with case/control status across the populations.  
Genomic inflation factors (lambda) were calculated for the trend tests as a metric of the 
amount of genomic inflation observed in the populations.  Lambda values >1 indicates 
the presence of population structure in the combined cases and controls possibly due to 
divergent ancestry or genotyping error.   
For the All ARDS and 1000 Genomes group, 168,309 SNPs with 2 alleles were 
matched by location between the cases and controls (of 169,376 total SNPs).   The trend 
test lambda=5.25, indicating the need for data filtering and correction for population 
structure.  When the data is filtered using the earlier described method (29,617 SNPs 
remaining) the lambda decreases to 2.48.  Of the principal components, PCs 1-6 and 9 
were significantly associated (p<1x10-3) with case-control status.  After correction for 9 
principal components, the lambda decreases to 1.35.  When outlier samples are removed 
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from the same 9 components, lambda decreases to 1.11.  When outlier removal is 
included in the PCA corrected trend test 45 samples are removed (all Caucasian cases) 
(figure 4).  
4.A  
4.B  
λ=2.48 
λ=1.35 
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4.C  
Figure 4: Quantile-Quantile Plots of Genotypic Trend Test 2 Values for the 
ARDS and 1000 Genomes Project Population.   
The straight line on each plot represents y=x.  A) QQ plot of expected 2 
values versus the actual 2 values for the genotypic trend test of case-control 
status. The data is filtered on HWE, LD, and SNP call rate but not PCA 
corrected.  B) QQ plot of expected 2 values versus the actual 2 values for 
the genotypic trend test of case-control status.  The data have been filtered 
and corrected for 9 PCs.  C) QQ plot of expected 2 values versus the actual 
2 values for the genotypic trend test of case-control status.  The data have 
been filtered and corrected for 9 PCs and undergone sample outlier removal. 
 
 
The Caucasian ARDS patients and EUR have 110,862 SNPs with 2 alleles in the 
combined population.  The trend test of the unfiltered data has a lambda value of 2.07.  
When the data is filtered (28, 681 SNPs remaining) the lambda decreases to 1.3.  Of the 
principal components calculated, 1, 3, 5, and 6 were significantly associated with case-
control status (p<1x10-3).  6 PCs were identified for correction and the lambda of the 
λ=1.11 
ARDS vs. 1000 Genomes with PCA Correction for 9 PCs 
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PCA corrected trend test is 1.20.  After PCA correction and outlier removal of 21 
samples (all cases) the lambda is 1.12.   
In the unfiltered data there are 129, 612 SNPs that are present in the African 
American ARDS patients and the AFR were used to assess the population structure.  The 
trend test of the unfiltered data had a lambda of 2.11 and after filtering (48,852 SNPs 
remaining) 1.70 (48, 852 SNPs remaining).  Principal components 1, 2, 19, and 20 were 
significantly associated with case control status (p<1x10-3), so two versions of the PCA 
correction were done- the first, for 2 PCs and the 2nd for 20 PCs.  A trend test was first 
corrected for 2 PCs, with a lambda of 1.54.  No outliers were identified for removal from 
the first 2 PCs.  When a trend test is PCA corrected for 20 PCs the lambda value is 1.06.  
When a trend test is PCA corrected with outlier removal on 20 PCs 51 samples were 
removed including 16 cases and 35 controls, and the lambda is 1.00. 
To provide reference for PC adjusted genotypic trend tests, the trend test p-values 
for the 3 genotyped SNPs are provided for the uncorrected tests as well as the p-values 
from the PCA corrected tests that passed the pre-PCA data filtering.   Rs9605146 and 
rs78142040 passed filtering in the Caucasian ARDS and EA 1000 Genomes sub 
population.  By looking in the changes in p-values between uncorrected, PCA corrected, 
and PCA corrected with outlier removal, it is seen that the significance in genotype 
association with case-control status decreases when the association test is corrected for 
PCs, however the trend remains (table 16).   
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Table 16: A Summary of the 4 Genotyped SNPs and the Effect of the PCA and Outlier 
Removal on Their Genotypic Trend Test P-Values.   
    rs3848719 rs9605146 rs78142040 
ARDS and all 1000 
Genomes Passed filtering? no no no 
no PCA trend p-value  1.57E-5 4.27E-43 3.11E-47 
corrected for 10 PCs trend p-value NA NA NA 
corrected for 10 PCs 
with outlier removal on 10 
PCs trend p  NA NA NA 
AA ARDS and AA 1000 
Genomes passed filtering? no no no 
no PCA trend p-value 2.89E-04 5.38E-20 1.03E-18 
corrected for 2 PCs trend p-value NA NA NA 
corrected for 2 PCs 
with outlier removal on 2 
PCs trend p-value NA NA NA 
corrected for 20 PCs trend p-value NA NA NA 
corrected for 20 PCs 
with outlier removal on 20 
PCs trend p-value NA NA NA 
EA ARDS and EA 1000 
Genomes passed filtering? no yes yes 
no PCA trend p-value 4.76E-03 5.67E-27 1.52E-32 
corrected for 26PCs trend p-value NA 2.62E-13 1.19E-11 
corrected for 6 PCs 
with outlier removal on 6 
PCs trend p-value NA 2.17E-19 2.62E-04 
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CHAPTER 6 
DISCUSSION 
 
The ARDS population has similar ages across the subgroups.  The 60-day 
mortality is higher in the sepsis cases than pneumonia and higher in the African 
American cases than Caucasians, which correlates with previously reported literature37.  
The same is observed for the APACHE II scores.  Ventilator-free days were lower in 
sepsis cases than pneumonia cases as well as lower in African American cases than 
Caucasian.  
 
Whole-Exome Sequencing and Identification of SNPs Associated With Susceptibility 
 
Whole-exome sequencing was previously performed in 96 ARDS patients from the 
ARDSnet with the intent of identifying coding SNPs whose minor allele frequencies are 
significantly different in ARDS than those of healthy controls as well as identifying those 
novel SNPs who may be predictors of ARDS severity and outcome.  In the overall ARDS 
population 1,382,399 SNPs were detected by exome-seq (Table 2) and 490,015 SNPs per 
person on average compared to 714, 074 SNPs per person from 625 healthy control subjects 
in the 1000 human genome project. Among them, 169,376 SNPs overlapped between cases 
and controls. The majority of non-overlapping SNPs in ARDS patients may represent 
ARDS specific SNPs barring the individual variability, sequencing error and data analysis 
discrepancy. From 169,376 SNPs, there are 49,789 bi-allelic SNPs in all ARDS patient 
subgroups based on race and initiating etiologies: Caucasian sepsis, Caucasian pneumonia, 
 40 
 
African-American sepsis and African American pneumonia. These SNPs may represent 
sepsis or pneumonia etiology specific SNPs of ARDS. The reason why we initially focused 
on the identification of novel coding SNPs associated with ARDS in sepsis and pneumonia 
origins was that in the original ARDS patient population, sepsis and pneumonia etiologies 
accounted for most cases.   
 
Validation of selected three SNPs 
 
Among three selectively validated SNPs(rs78142040, rs9605146 and rs3848719 ) 
in additional 117 ARDS patients,  rs78142040 in ARSD is associated with increased 
ARDS susceptibility in the overall ARDS population (213 patients) as well as all racial 
and comorbidity subpopulations.  It approaches significant association with an increase in 
APACHEII score (p=0.061) when samples in the highest and lowest score quartiles are 
compared in ARDS patients.  rs78142040 is significantly associated (p<0.05) with an 
increase in 60-day mortality in the total ARDS population (p=0.017, OR=2.039, 95%CI 
1.130-3.681).  The lack of HWE in the 1000 Genomes Project population is contributed 
to by a lack of heterozygous samples (and very few minor alleles).  Associations with 
ventilator-free days and APACHE II (not in quartiles) score were not observed.  The 
molecular mechanism underlying these associations are presently unknown. The ARSD 
gene encodes a sulfatase that is associated with bone and cartilage development and has 
been previously identified as having involvement in sphingolipid metabolism (involved 
in signal transmission and cellular recognition) and as a potential biomarker for chronic 
lymphocytic leukemia21. ARSD protein isoforms have a highly conserved catalytic 
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peptide domain when compared with other arylsulfatases26,27.  ARSD is widely expressed 
and is suspected to play a role in housekeeping or multiple other processes, however 
specific substrates have not been identified28.  It was reported that there were changes in 
activities of lung lysosomal enzymes including sulfatase during ARDS38.  The SNP lies 
within a histone mark in intron 6 and possibly affects transcription thought this theory 
requires validation.  It may be interesting to explore whether rs78142040 causes the 
differential expression of ARSD, thus sulfatase activity, which may link its role in the 
pathogenesis of ARDS. While the SNP of interest in this gene is intronic, the strength of 
the association within the cases as well as in comparison with the healthy controls 
indicates its potential application as a biomarker.   
rs9605146 in XKR3 gene is associated with increased susceptibility in the ARDS 
population and all subgroups.  Associations with severity and mortality were not 
observed.  XKR3 is a member of the XK/Kell complex in the Kell blood group system. 
XKR3 is a homolog of XK, which is a putative membrane transporter.  XK is associated 
with McLeod syndrome (characterized by late-onset abnormalities in the central nervous 
system and neuromuscular system) and red cell acanthocytosis22.  XKR3 has previously 
been indicated as a potential biomarker for blood transfusion compatibility29. While it is 
currently unknown what underlies the association of rs9605146 with susceptibility in the 
ARDS,  it causes a deleterious amino acid coding change from proline to leucine in XKR3 
as predicted by Provean (score=-5.494), make rs9605146 a legitimate candidate for 
further study of its role in the pathogenesis of ARDS. 
rs3848719 in ZNF335 approaches association with increased susceptibility in the 
exome-sequenced and overall ARDS population.  The SNP is associated with a reduction 
 42 
 
in APACHE II score when the highest and lowest score quartiles are compared in the 
total ARDS population (p=0.032, OR=0.55, 95%CI 1.27-2.05). The SNP is also 
associated with increased 60-day mortality in Caucasian and pneumonia groups in the 
genotyped samples, suggesting that this SNP could be a good predictor of outcome in 
Caucasian populations and in patients with pneumonia, however theses associations were 
not observed in the overall population.  . It is a synonymous SNP in the 5th exon of the 
Zinc-Finger/Leucine-Zipper Co-Transducer NIF1 gene (ZNF335). ZNF335 is involved in 
neural progenitor cell proliferation and self-renewal as a component of the vertebrate-
specific, trithorax H3K4-methylation complex.  ZNF335 is associated with microcephaly 
(a neurodevelopmental disorder), small somatic size and neonatal death.  The gene is 
essential as homozygous knockout mouse models have a lethal effect 23,24.  The role of 
the gene in cellular differentiation and gene expression could implicate an effect on the 
fundamental physiology and neural signaling in the lungs, contributing to the 
pathogenesis of ARDS.  
All SNPs are in Hardy-Weinberg Equilibrium (HWE p>1x10-4) in the total ARDS 
cases. Rs3848719 is in HWE in the EUR + AFR 1000 Genomes and AFR 1000 Genomes 
subgroup and all 3 are in HWE in the EUR 1000 Genomes subgroup (supplementary 
table 1).   
We selectively genotyped and validated three SNPs(rs78142040, rs9605146 and 
rs3848719 ) in additional 117 ARDS patients using the TaqMan genotype assay and 
performed in depth association analyses of these SNPs with the susceptibility, severity 
and outcome to ARDS in a combined 213 ARDS patients (96 by exome-seq +117 by 
TaqMan=213). These validations lend a solid support to the validity and prowess of 
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novel ARDS associated SNP identifications by exome-seq. This study provides a rich 
resource for further experimentation and replication to develop and establish new genetic 
biomarkers and therapeutic targets to ARDS.   The further replicates of all these SNPs in 
different and larger patient populations and mechanistic explorations of these SNPs in 
cell culture and animal models may lead to the development of these novel SNPs as new 
diagnostic biomarkers and therapeutic targets to ARDS in the near future.  
 
Limitations 
 
 
Although we applied the Bonferroni correction (p<2.95x10-7) and several SNP 
filtering steps during our data analysis as well as validations of three selected candidate 
SNPs, our data come with some potential limitations. Firstly, we only performed exome-
sequencing of 96 ARDS patient samples. Although we would argue that this is a very 
reasonable sample size considering the high cost of exome-sequencing (even the exome-
seq cost per sample is cheaper than whole genome-seq per sample), the sample size is not 
large. Our 89 SNPs which are strongly associated with susceptibility are all present in an 
age and race matched 48 sample control set (coriell.org), which will be used to validate 
our findings in further studies (117,35 out of the 169,376 SNPs which are in the ARDS 
cases and 1000 Genomes  Project are found in this control set).  Confirmation of our 
findings in additional larger patient populations is warranted. Second, during analysis of 
SNP associations with ARDS susceptibility, we used the healthy control subjects from 
the 1000 genome project. Both ARDS patients and healthy control subjects aren’t derived 
from the same population. We have applied HWE and LD filtering, PCA analysis and Q-
Q plot visualization as well as race specific comparison to filter the identified SNPs to 
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better quantify the amount of structure, though these steps may not totally correct the 
population admixtures.     
It is expected that population admixture may be responsible for some of the 
observed population structure in our dataset, however we can’t determine if genomic 
inflation is uniform across the genome.  Lambda values improved with the pre-PCA 
filtering, which suggests that this method is only effective for quantifying error in SNPs 
that are inherited in LE and HWE.  It is possible that SNPs that are genuinely associated 
with a disease may not follow the expected linkage equilibrium (LE) or Hardy-Weinberg 
Equilibrium (HWE) distributions, and these SNPs are typically removed from the dataset 
prior to principal components analysis (PCA) because they can bias corrections made for 
population stratification SNPs that don’t meet the criteria for PCA are still interesting and 
viable therapeutic targets. Adjusting the trend tests for the largest principal components 
caused a decrease in Lambda confirming a reduction in population structure with 
correction, and again when samples that were outliers from the top principal components 
were removed from analysis.    In all principal component adjustments the resulting qq 
plots better approximate the expected x=y line for correlation χ2 vs. expected trend χ2 
after adjustment for the PCs with the exception of the African American ARDS and AFR 
1000 Genomes Project population where correcting for 20 PCs with outlier removal 
overcorrected the data.  Since the number of cases is small the outlier removal step of the 
PCA analysis is not practical for drawing for subsequent statistical analyses and the 
identification of candidate variants in this population.    
Replication of our findings in larger and different populations may strengthen and 
develop here identified candidate SNPs as true genetic biomarkers of ARDS. Mechanistic 
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explorations of these SNPs in cell culture and animal models may lead to the clinical 
application of these novel SNPs as new diagnostic biomarkers and therapeutic targets to 
ARDS in the near future.  With a better understanding of the genetic components of 
ARDS it will be possible to create novel gene therapies that could significantly reduce the 
mortality and morbidity of ARDS.  
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CHAPTER 7 
CONCLUSIONS 
 
The primary focus of this study is to identify genetic components of ARDS 
susceptibility, severity and outcome.  Whole exome-sequencing has identified a number 
of potential ARDS association SNPs. This study selectively validated 3 SNPs that are 
associated with the susceptibility (rs78142040 and rs9605146), severity (rs3848719) and 
outcome (rs78142040 and rs3848719) of ARDS.  More validations in a larger patient 
population with matched controls as well as further investigation of the underlying 
molecular mechanisms are needed.  Further research on the topic can include biological 
validation in cellular and mouse models as well as computational modeling validation.  
Possible implications of the study could be to provide novel diagnostic and therapeutic 
targets for ARDS.  With a better understanding of the genetic components of ARDS it 
could be possible to develop new or better therapeutic modalities that could significantly 
reduce mortality and morbidity of ARDS in the long run.   
  
 47 
 
APPENDIX A 
SUPPLEMENTARY TABLES AND FIGURES 
 
 
S1.A  
 
S1.B  
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S1.C  
 
S1.D  
 
Supplementary figure 1.  Manhattan Plots of the EUR Cases and Controls and the AFR 
Cases and Controls, Respectively. 
 (A)A Manhattan plot of –log10 (2 p-value) by the chromosomal location of the 
Caucasian ARDS compared with the EUR 1000 Genomes participants.  (B) A Manhattan 
plot of the same data as A with a zoomed in Y-axis.  (C)A Manhattan plot of –log10 (2 
p-value) by the chromosomal location of the African American ARDS compared with the 
AFR 1000 Genomes participants.  (D) A Manhattan plot of the same data as C with a 
zoomed in Y-axis.    
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Supplementary table 1: The Call Rate and Hardy-Weinberg Equilibrium P-values 
of the 4 SNPs in the 96 Exome Sequenced Patients and 1000 Genomes Project 
Population and Subgroups.   
SNP rs78142040     
Gene ARSD     
 Cases Controls Cases + Controls 
ARDS P-value 1.77E-2 6.11E-138 4.75E-2 
Caucasian P-value 8.31E-2 1 5.75E-1 
African American P-value 7.90E-2 1.93E-55 5.29E-4 
Pneumonia P-value 2.23E-1 6.11E-138 4.19E-8 
Sepsis P-value 2.70E-2 6.11E-138 3.92E-4 
African American Sepsis P-value 5.81E-2 1.93E-55 3.61E-2 
African American Pneumonia P-value 4.16E-1 1.93E-55 2.41E-12 
Caucasian Sepsis P-value 1.22E-1 1 7.26E-1 
Caucasian Pneumonia P-value 3.55E-1 1 8.22E-1 
SNP rs9605146     
Gene XKR3     
 Cases Controls Cases + Controls 
ARDS P-value 3.78E-1 5.13E-15 2.35E-21 
Caucasian P-value 2.02E-1 4.36E-2 6.27E-9 
African American P-value 3.88E-1 2.16E-16 3.45E-14 
Pneumonia P-value 7.61E-1 5.13E-15 1.83E-16 
Sepsis P-value 1.16E-1 5.13E-15 1.60E-22 
African American Sepsis P-value 1.22E-1 2.16E-16 1.17E-12 
African American Pneumonia P-value 8.47E-1 2.16E-16 2.85E-17 
Caucasian Sepsis P-value 9.24E-3 4.36E-2 3.09E-11 
Caucasian Pneumonia P-value 3.84E-1 4.36E-2 5.22E-3 
SNP rs3848719     
Gene ZNF335     
 Cases Controls Cases + Controls 
ARDS P-value 3.81E-6 4.76E-3 2.30E-6 
Caucasian P-value 2.64E-3 4.41E-1 6.23E-1 
African American P-value 7.26E-4 2.44E-1 7.67E-2 
Pneumonia P-value 2.09E-3 4.76E-3 1.88E-4 
Sepsis P-value 5.60E-4 4.76E-3 9.10E-5 
African American Sepsis P-value 2.04E-2 2.44E-1 6.48E-1 
African American Pneumonia P-value 1.40E-2 2.44E-1 6.43E-1 
Caucasian Sepsis P-value 1.46E-2 4.41E-1 9.94E-1 
Caucasian Pneumonia P-value 7.42E-2 4.41E-1 8.31E-1 
These values were taken into account in the selection of the SNPs for genotyping 
in the additional population. 
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Supplementary table 2:   Linear Regression with APACHE II Score.   
 
SNP  rs78142040    
Gene ARSD   
 96 Exome 117 TaqMan Total 213 
ARDS R2 0.005521 0.01224 0.010852 
EA ARDS R2 0.018964 0.002823 0.000723 
AA ARDS R2 0.022106 0.215676 0.016704 
Pneumonia R2 0.000523 0.000903 0.000365 
Sepsis R2 0.003156 0.021868 0.014571 
AA Sepsis R2 0.084892 0.118034 0.000143 
AA Pneumonia R2 0.049196 0.367781 0.028425 
EA Sepsis R2 0.0198 0.003489 0.001723 
EA Pneumonia R2 0.000702 0.043586 0.014079 
SNP   rs9605146   
Gene XKR3   
 96 Exome 117 TaqMan Total 213 
ARDS R2 0.048143 0.012997 0.000497 
EA ARDS R2 0.049544 0.020126 0.001013 
AA ARDS R2 0.01239 0.101041 0.013936 
Pneumonia R2 0.039067 0.085527 0.013693 
Sepsis R2 0.071783 0.001684 0.02047 
AA Sepsis R2 0.13201 0.004314 0.009831 
AA Pneumonia R2 0.002553 0.343422 0.092252 
EA Sepsis R2 0.053535 0.002677 0.022779 
EA Pneumonia R2 0.056131 0.085977 0.009475 
SNP rs3848719   
Gene ZNF335   
 96 Exome 117 TaqMan Total 213 
ARDS R2 0.062995 0.005162 0.023751 
EA ARDS R2 0.001195 0.000516 0.000861 
AA ARDS R2 0.215301 0.001016 0.070074 
Pneumonia R2 0.166849 0.001253 0.014435 
Sepsis R2 0.029758 0.035016 0.041493 
AA Sepsis R2 0.340003 0.191067 0.177648 
AA Pneumonia R2 0.155128 0.044786 0.00434 
EA Sepsis R2 0.064841 0.001605 4.24E-05 
EA Pneumonia R2 0.058004 0.008149 0.002669 
This table shows the results of the linear regression (additive 
model).  Associations were considered to be significant if R2>0.8. 
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Supplementary table 3:   Linear Regression with Ventilator-Free Days per 
28 Days.   
SNP rs78142040   
Gene  ARSD   
 96 Exome 117 TaqMan Total 213 
ARDS R2 0.015259 0.033802 0.026054 
EA ARDS R2 0.025028 0.000407 0.006519 
AA ARDS R2 0.001615 0.184596 0.019431 
Pneumonia R2 0.013639 5.37E-05 0.003439 
Sepsis R2 0.003739 0.088682 0.042303 
AA Sepsis R2 0.022886 0.406296 0.053339 
AA Pneumonia R2 0.005096 0.03435 0.007386 
EA Sepsis R2 0.017498 0.002952 0.007018 
EA Pneumonia R2 0.007463 0.004356 9.83E-05 
SNP rs9605146   
Gene  XKR3   
 96 Exome 117 TaqMan Total 213 
ARDS R2 0.018928 0.007354 0.000112 
EA ARDS R2 0.004794 0.029358 0.003427 
AA ARDS R R2 0.048353 1.17E-05 0.01857 
Pneumonia R2 0.083303 0.022224 0.00073 
Sepsis R2 0.00051 0.001202 4.27E-05 
AA Sepsis R2 0.030121 0.02358 0.000308 
AA Pneumonia R2 0.065061 0.037774 0.056542 
EA Sepsis R2 9.04E-05 0.000829 0.000312 
EA Pneumonia R2 0.035209 0.088483 0.012099 
SNP rs3848719   
Gene  ZNF335   
 96 Exome 117 TaqMan Total 213 
ARDS R2 7.29E-05 7.24E-05 0.000112 
EA ARDS R2 0.022345 0.017442 0.014008 
AA ARDS R2 0.024184 0.006926 0.009665 
Pneumonia R2 0.031582 0.033899 0.001198 
Sepsis R2 0.012915 0.037174 0.0031 
AA Sepsis R2 0.024291 0.114525 0.000487 
AA Pneumonia R2 0.032883 0.034291 0.034885 
EA Sepsis R2 0.071066 0.008406 0.005712 
EA Pneumonia R2 0.000707 0.10277 0.028252 
   
This table shows the R2 results of the linear regression (additive 
model).  Associations were considered to be significant if R2 >0.8. 
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S2.A S2.B  
S2.C  
Supplementary Figure 2: Scree Plots of the Eigenvalues Generated by Principal Component Analysis. The largest eigenvalues are used 
in corrections for population structure.  A) The All ARDS and AFR+EUR 1000 Genomes population eigenvalues.  720 principal 
components were measured and the largest eigenvalue is 17.09.  B) The Caucasian ARDS and EUR ARDS population eigenvalues.  449 
principal components were measured and the largest eigenvalue is 1.52.  C) The African American ARDS and AFR 1000 Genomes 
population eigenvalues.  272 principal components were measured and the largest eigenvalue is 1.67.  
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S3.C  
Supplementary figure 2:  Scatter Plots of the Principal Component Values. 
The principal component values for the first 2 eigenvalues are plotted 
against each other where the cases are in blue and the controls in green.  
A) The All ARDS and 1000 Genomes population principal components.  
B) The Caucasian ARDS and EUR ARDS population principal 
components.  C) The African American ARDS and AFR 1000 Genomes 
population principal components.
 
 
 
 
 
 55 
 
S4.A  
S4.B  
λ=1.20 
λ=1.30 
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S4.C  
Figure 5: Quantile-Quantile Plots of Genotypic Trend Test 2 Values for the 
Caucasian ARDS and EUR 1000 Genomes Comparison. 
The straight line on each plot represents y=x.  A) QQ plot of expected 2 
values versus the actual 2 values for the genotypic trend test of case-control 
status. The data is filtered on HWE, LD, and SNP call rate but not PCA 
corrected.  B) QQ plot of expected 2 values versus the actual 2 values for 
the genotypic trend test of case-control status.  The data have been filtered 
and corrected for 6 PCs.  C) QQ plot of expected 2 values versus the actual 
2 values for the genotypic trend test of case-control status.  The data have 
been filtered and corrected for 6 PCs and undergone sample outlier removal. 
 
 
 
 
 
λ=1.12 
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S5.A  
S5.B  
λ=1.70 
λ=1.54 
 58 
 
S5.C  
S5.D  
Figure 6: Quantile-Quantile plots of Genotypic Trend test 2 Values for the 
African American ARDS and AFR 1000 Genomes Comparison.   
The straight line on each plot represents y=x.  A) QQ plot of expected 2 
values versus the actual 2 values for the genotypic trend test of case-control 
status. The data is filtered on HWE, LD, and SNP call rate but not PCA 
corrected.  B) QQ plot of expected 2 values versus the actual 2 values for 
the genotypic trend test of case-control status.  No samples were identified 
for outlier removal.   C) QQ plot of expected 2 values versus the actual 2 
for the genotypic trend test of case-control status.  The data have been 
filtered and corrected for 20 PCs.  D) QQ plot of expected 2 values versus 
the actual 2 values for the genotypic trend test of case-control status.  The 
data have been filtered and corrected for 20 PCs and undergone sample 
outlier removal. 
λ=1.06 
λ=1.00 
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